June 1, 2025
Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a […]
May 31, 2025
TOPLINE In patients with advanced Claudin-18 isoform 2 (CLDN18.2) -positive gastric or gastroesophageal junction cancers, satricabtagene autoleucel (satri-cel) chimeric antigen receptor (CAR) T-cell therapy significantly extended […]
May 31, 2025
In the treatment of newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), patients who fail to achieve initial molecular response with the third-generation tyrosine kinase […]
May 31, 2025
Treatment with pembrolizumab and the antibody-drug conjugate (ADC) sacituzumab govitecan improved progression-free survival (PFS) in patients with PD-L1-positive locally advanced or metastatic triple-negative breast cancer (TNBC) […]
May 30, 2025
TOPLINE: At a median follow-up of 13.2 years, dose-escalated hypofractionated intensity-modulated radiation therapy led to fewer treatment failures in men with localized, intermediate-risk prostate cancer than […]
May 29, 2025
In 2005, Roy Brosgole, then 38, was a busy working parent. He commuted about an hour each way to a teaching job in New York City […]
May 29, 2025
Pfizer was taken to task at a recent meeting of the US Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee (ODAC) for attempting to expand […]
May 29, 2025
(Reuters) -Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients […]
May 29, 2025
More than 60% of patients with cervical cancer and 30% of those with endometrial cancer are diagnosed at an advanced stage, when survival rates are lowest. […]